Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

PreveCeutical (CSE:PREV) selects ICON PLC for painkiller clinical development

Caroline Egan , The Market Herald Canada
0 Comments| February 7, 2023

{{labelSign}}  Favorites
{{errorMessage}}

  • PreveCeutical Medical Inc. (PREV) has selected ICON PLC to complete work on the analgesic program’s clinical development
  • PreveCeutical’s analgesic program is designing a non-addictive painkiller to meet the requirements due to the global abuse of painkillers
  • ICON is a global healthcare intelligence and clinical research organization that provides outsourced services
  • PreveCeutical will begin clinical development with ICON during its first fiscal quarter and work with regulators for any potential fast-track provisions
  • PreveCeutical Medical Inc. (PREV) is up 16.67 per cent, trading at $0.03 per share as of 1:35 p.m. EST

PreveCeutical Medical (PREV) has selected ICON PLC to complete work on the analgesic program’s clinical development.

PreveCeutical is a health sciences company that develops options for preventive and curative therapies utilizing organic and natural products. Its analgesic program is designing a non-addictive painkiller to meet the requirements due to the global abuse of painkillers.

ICON is a global healthcare intelligence and clinical research organization. It provides outsourced services to pharmaceutical, biotechnology, medical device, government, and public health organizations.

PreveCeutical will begin clinical development with ICON during its first fiscal quarter and work with regulators for any potential fast-track provisions.

The work will include conducting a comprehensive gap analysis to confirm current conclusions as well as identify any potential additional nonclinical studies that will be needed to support Investigational New Drug and Clinical Trial Application submissions.

ICON will also help with the construction of a clinical development plan for the program’s phase one through phase three studies.

PreveCeutical’s CEO, Stephen Van Deventer, commented,

“After many reviews of the best global CROs, we have selected ICON as we believe that they are one of the best in the world, with experience in all clinical matters and, more importantly, pain treatment therapies.”

PreveCeutical Medical Inc. (PREV) is up 16.67 per cent, trading at $0.03 per share as of 1:35 p.m. EST.




{{labelSign}}  Favorites
{{errorMessage}}